A PHASE 1 DRUG-DRUG INTERACTION STUDY BETWEEN BRIGATINIB AND THE CYP3A SUBTRATE MIDAZOLAM IN PATIENTS WITH ALK-POSITIVE OR ROS1-POSITIVE SOLID TUMORS
2018-001624-19TUMORES SÓLIDOS POSITIVOS AVANZADOSFundación Jiménez DíazInvestigador: MORENO GARCIA VICTOR